Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co, has entered into a definitive agreement to transfer ownership of its Research Triangle Park (RTP) manufacturing campus to Biogen Inc. This arrangement expands upon the capacity-sharing manufacturing alliance Eisai and Biogen have had in place at the RTP facility since early 2013. About 100 Eisai employees will be offered jobs at Biogen when the deal closes.

The property ownership transfer comprises all buildings on the campus. The parenteral facility will be transferred immediately upon closing of the transaction and the oral solid-dose facility will be transferred after the expiration of an existing short-term lease. Parenteral refers to medicines administered other than orally, usually via injection.

As part of this arrangement, Eisai anticipates approximately 100 employees will be offered employment at Biogen, effective upon deal closing.

Under the new agreement, Biogen will continue to make oral solid-dose products for Eisai.

Eisai says it will continue to base its global partnership management, quality assurance, supply chain and business support staff in North Carolina to manage a seamless supply chain. These functions will remain on the current RTP campus for a six-month transition period until Eisai has secured new office space. In addition, the company will continue to manufacture product at its facility in Baltimore, MD.

“The decision to transfer ownership of the RTP campus is part of a global supply chain initiative to optimize Eisai’s logistics strategy in support of our long-term business objectives,” said Lou Arp, general manager of the Eisai RTP site and president of the Global Oncology Manufacturing Unit for Eisai Inc.said in a statement.

“The decision to transfer ownership of the RTP campus is part of a global supply chain initiative to optimize Eisai’s logistics strategy in support of our long-term business objectives,” said Lou Arp, general manager of the Eisai RTP site and president of the Global Oncology Manufacturing Unit for Eisai Inc.

Closing of the transaction requires regulatory approvals.